scholarly journals Reply to: “Selection of MRI contrast agent and diagnostic criteria for HCC to maximize the advantages of contrast agents”

2020 ◽  
Vol 73 (3) ◽  
pp. 716-717
Author(s):  
Anita Paisant ◽  
Valérie Vilgrain ◽  
Christophe Aubé
2021 ◽  
Vol 11 (3) ◽  
pp. 1165
Author(s):  
Wen-Tien Hsiao ◽  
Yi-Hong Chou ◽  
Jhong-Wei Tu ◽  
Ai-Yih Wang ◽  
Lu-Han Lai

The purpose of this study is to establish the minimal injection doses of magnetic resonance imaging (MRI) contrast agents that can achieve optimized images while improving the safety of injectable MRI drugs. Gadolinium-diethylenetriamine penta-acetic acid (Gd-DTPA) and ferucarbotran, commonly used in clinical practice, were selected and evaluated with in vitro and in vivo experiments. MRI was acquired using T1-weighted (T1W) and T2-weighted (T2W) sequences, and the results were quantitatively analyzed. For in vitro experiments, results showed that T1W and T2W images were optimal when Gd-DTPA-bisamide (2-oxoethyl) (Gd-DTPA-BMEA) and ferucarbotran were diluted to a volume percentage of 0.6% and 0.05%; all comparisons were significant differences in grayscale statistics using one-way analysis of variance (ANOVA). For in vivo experiments, the contrast agent with optimal concentration percentages determined from in vitro experiments were injected into mice with an injection volume of 100 μL, and the images of brain, heart, liver, and mesentery before and after injection were compared. The statistical results showed that the p values of both T1W and T2W were less than 0.001, which were statistically significant. Under safety considerations for MRI contrast agent injection, optimized MRI images could still be obtained after reducing the injection concentration, which can provide a reference for the safety concentrations of MRI contrast agent injection in the future.


RSC Advances ◽  
2021 ◽  
Vol 11 (51) ◽  
pp. 32216-32226
Author(s):  
Ramesh Marasini ◽  
Sagar Rayamajhi ◽  
Anthony Moreno-Sanchez ◽  
Santosh Aryal

In pursuit of safer alternatives to Gd-based MRI contrast agents due to its toxicity and organ deposition, herein, we developed a safer and efficient clinically relevant iron(iii) chelated polymeric nanoparticle as a T1-weighted MRI contrast agent.


2020 ◽  
Vol 13 (10) ◽  
pp. 296
Author(s):  
Friederike Reeßing ◽  
Sèvrin E. M. Huijsse ◽  
Rudi A. J. O. Dierckx ◽  
Ben L. Feringa ◽  
Ronald J.H. Borra ◽  
...  

Thanks to its innocuousness and high spatiotemporal resolution, light is used in several established and emerging applications in biomedicine. Among them is the modulation of magnetic resonance imaging (MRI) contrast agents’ relaxivity with the aim to increase the sensitivity, selectivity and amount of functional information obtained from this outstanding whole-body medical imaging technique. This approach requires the development of molecular contrast agents that show high relaxivity and strongly pronounced photo-responsiveness. To this end, we report here the design and synthesis of a light-activated MRI contrast agent, together with its evaluation using UV–vis spectroscopy, Fast Field Cycling (FFC) relaxometry and relaxometric measurements on clinical MRI scanners. The high relaxivity of the reported agent changes substantially upon irradiation with light, showing a 17% decrease in relaxivity at 0.23T upon irradiation with λ = 400 nm (violet) light for 60 min. On clinical MRI scanners (1.5T and 3.0T), irradiation leads to a decrease in relaxivity of 9% and 19% after 3 and 60 min, respectively. The molecular design presents an important blueprint for the development of light-activatable MRI contrast agents.


2016 ◽  
Vol 7 (7) ◽  
pp. 4230-4236 ◽  
Author(s):  
Lyndsay M. Randolph ◽  
Clare L. M. LeGuyader ◽  
Michael E. Hahn ◽  
Christopher M. Andolina ◽  
Joseph P. Patterson ◽  
...  

A Gd3+-coordinated polymerizable analogue of the MRI contrast agent Gd-DOTA was used to prepare amphiphilic block copolymers, with hydrophilic blocks composed entirely of the polymerized contrast agent.


2017 ◽  
Vol 41 (7) ◽  
pp. 2735-2744 ◽  
Author(s):  
Abhishek Gupta ◽  
Liliana de Campo ◽  
Lynne J. Waddington ◽  
Robert B. Knott ◽  
Dennis Hwang ◽  
...  

A novel paramagnetic amphiphile designed to form nanoassemblies of highly ordered nanostructures was explored as an advanced MRI contrast agent.


2015 ◽  
Vol 3 (11) ◽  
pp. 2241-2276 ◽  
Author(s):  
Erwin Peng ◽  
Fenghe Wang ◽  
Jun Min Xue

The development of water-soluble nanostructured magnetic nanocomposites based on hydrophobic magnetic nanoparticle assemblies using an organic functional coating for MRI contrast agent applications was discussed.


2015 ◽  
Vol 112 (21) ◽  
pp. 6607-6612 ◽  
Author(s):  
Shenghui Xue ◽  
Hua Yang ◽  
Jingjuan Qiao ◽  
Fan Pu ◽  
Jie Jiang ◽  
...  

With available MRI techniques, primary and metastatic liver cancers that are associated with high mortality rates and poor treatment responses are only diagnosed at late stages, due to the lack of highly sensitive contrast agents without Gd3+ toxicity. We have developed a protein contrast agent (ProCA32) that exhibits high stability for Gd3+ and a 1011-fold greater selectivity for Gd3+ over Zn2+ compared with existing contrast agents. ProCA32, modified from parvalbumin, possesses high relaxivities (r1/r2: 66.8 mmol−1⋅s−1/89.2 mmol−1⋅s−1 per particle). Using T1- and T2-weighted, as well as T2/T1 ratio imaging, we have achieved, for the first time (to our knowledge), robust MRI detection of early liver metastases as small as ∼0.24 mm in diameter, much smaller than the current detection limit of 10–20 mm. Furthermore, ProCA32 exhibits appropriate in vivo preference for liver sinusoidal spaces and pharmacokinetics for high-quality imaging. ProCA32 will be invaluable for noninvasive early detection of primary and metastatic liver cancers as well as for monitoring treatment and guiding therapeutic interventions, including drug delivery.


2016 ◽  
Vol 7 ◽  
pp. 1086-1103 ◽  
Author(s):  
Nikodem Kuźnik ◽  
Mateusz Michał Tomczyk

Magnetic resonance imaging (MRI) is one of the most commonly used tomography techniques in medical diagnosis due to the non-invasive character, the high spatial resolution and the possibility of soft tissue imaging. Contrast agents, such as gadolinium complexes and superparamagnetic iron oxides, are administered to spotlight certain organs and their pathologies. Many new models have been proposed that reduce side effects and required doses of these already clinically approved contrast agents. These new candidates often possess additional functionalities, e.g., the possibility of bioactivation upon action of particular stimuli, thus serving as smart molecular probes, or the coupling with therapeutic agents and therefore combining both a diagnostic and therapeutic role. Nanomaterials have been found to be an excellent scaffold for contrast agents, among which carbon nanotubes offer vast possibilities. The morphology of multiwalled carbon nanotubes (MWCNTs), their magnetic and electronic properties, the possibility of different functionalization and the potential to penetrate cell membranes result in a unique and very attractive candidate for a new MRI contrast agent. In this review we describe the different issues connected with MWCNT hybrids designed for MRI contrast agents, i.e., their synthesis and magnetic and dispersion properties, as well as both in vitro and in vivo behavior, which is important for diagnostic purposes. An introduction to MRI contrast agent theory is elaborated here in order to point to the specific expectations regarding nanomaterials. Finally, we propose a promising, general model of MWCNTs as MRI contrast agent candidates based on the studies presented here and supported by appropriate theories.


RSC Advances ◽  
2017 ◽  
Vol 7 (55) ◽  
pp. 34892-34900 ◽  
Author(s):  
V. Nandwana ◽  
S.-R. Ryoo ◽  
S. Kanthala ◽  
A. Kumar ◽  
A. Sharma ◽  
...  

Here we report the development of a “natural” MRI contrast agent with tunable Fe loading and a magnetic core for magnetic resonance imaging.


Sign in / Sign up

Export Citation Format

Share Document